Research feed
Recently published diabetes studies added to Dediabetes, summarized and organized by intervention and outcome.
Sorted by publication date. Some studies may have been added to Dediabetes later.
Orforglipron treatment led to significant reductions in cardiovascular risk markers among participants with type 2 diabetes and obesity.
This study evaluated the cardiorenal effects of semaglutide in individuals with type 2 diabetes at high cardiovascular risk, finding significant reductions in major adverse cardiovascular events.
This study evaluated the impact of semaglutide on kidney and cardiovascular risks in individuals with type 2 diabetes and chronic kidney disease, finding significant reductions in key health outcomes.
The study evaluated the effects of semaglutide on cardiovascular events in individuals with overweight or obesity and established cardiovascular disease without diabetes, finding a 20% reduction in major adverse cardiovascular events.
Telehealth through SMS reminders significantly improved statin adherence and reduced cholesterol levels in patients with diabetes.
A home-based lifestyle intervention with telemedicine support showed modest effects on HbA1c levels in patients with coronary heart disease and type 2 diabetes.
This study evaluated the effects of canagliflozin combined with metformin on cardiovascular risk in patients with type 2 diabetes mellitus, finding a significant reduction in major adverse cardiovascular events.
The J-DOIT3 trial analyzed the effects of intensified multifactorial intervention on glycemic management in type 2 diabetes, finding that intensive therapy reduced the risk of retinopathy onset.
This study evaluated the effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes, finding a 14% reduction in major adverse cardiovascular events compared to placebo.
This study compared the real-world effectiveness of SGLT2 inhibitors and DPP4 inhibitors in patients with type 2 diabetes and cardiovascular disease, finding that SGLT2 inhibitors were associated with lower risks of major adverse cardiovascular events.
